https://www.selleckchem.com/pr....oducts/pemigatinib-i
To evaluate the impact of baseline resistance-associated substitutions (RAS) on direct-acting antivirals (DAAs) treatment response among the pegylated interferon in combination with ribavirin (PR) failing patients in a real-life setting. Blood samples and clinical data from 171 patients who failed PR treatment were collected. ALL of them were received rescued DAAs regimen. RAS identified in the NS3, NS5A and NS5B regions by Sanger sequencing method were compared by DAA regimen and HCV subtypes. We assessed SVR12 and evalu
Like
Comment
Share
